Journal Article

Treatment with tofacitinib attenuates muscle loss through myogenin activation in the collagen-induced arthritis

Loch, Sofia, Pedó, Renata Ternus, Xavier, Ricardo Machado, Gasparini, Maria Luísa, do Espírito Santo, Rafaela Cavalheiro, Farinon, Mirian, Karnopp, Thais, de Souza Silva, Jordana Miranda, da Rosa, Thales Hein, di Domenico, Andressa, Chapacais, Gustavo, Bartikoski, Bárbara Jonson, dos Santos, Leonardo Peterson

2024

Overview

BackgroundSarcopenia is a muscle disease characterized by reduction of muscle strength and muscle mass. In RA, 25.9 to 43.3% of the patients present sarcopenia. The loss of muscle mass observed in RA patients occurs either by activation of catabolic pathways or by inhibition of anabolic pathways. Despite having a list of drugs capable of treating RA inflammation, their effect on muscle is unclear. Our objective was to evaluate the tofacitinib effect on the muscle mass of collagen-induced arthritis (CIA) mice.MethodsCIA was induced in male DBA/1J mice by subcutaneous injection of Type 2 Collagen plus Freund Adjuvant. Animals were randomized into 3 groups: CIA + tofacitinib; CIA + vehicle; and healthy controls. Treatment was administered twice a day, between days 18 and 45 after induction. Clinical score, edema, and body weight were evaluated during the experimental period. After euthanasia, tibiotarsal joints were collected for assessment of disease histopathological score, and tibialis anterior (TA) and gastrocnemius (GA) muscles were weighed to assess muscle mass. Muscle atrophy was evaluated by measurement of TA myofiber cross-sectional area (CSA). Protein expression was evaluated by western blot using GA homogenates. Serum inflammatory markers were evaluated by ELISA. Statistical analysis included ANOVA followed by Tukey’s or with Kruskal-Wallis. The statistical difference was assumed for p < 0.05.ResultsTofacitinib treatment decreased arthritis severity by reducing clinical score, and hind paw edema in comparison with the vehicle group. Tofacitinib showed weight gain, higher TA and GA weights, and increased CSA compared to the vehicle group. On day 45, Tofacitinib presented increased muscle strength compared to the vehicle group, however, no difference was found in muscle fatigue. Pax7 expression was unchanged, while MyoD expression showed an increasing trend, and myogenin expression was significantly increased in Tofacitinib compared to vehicle and control groups. The treatment didn’t modify Murf-1 expression. Tofacitinib mice showed decreased serum levels of TNF and increased IL-6 serum levels.ConclusionTofacitinib attenuated muscle loss in arthritic mice, increased muscle weight and muscle CSA. Activation of satellite cell regeneration, based on the increased expression of myogenin, is a potential mechanism involved in tofacitinib action against muscle loss.

• Publisher: Springer Nature B.V
• Subject: Animals / Arthritis / Atrophy / Cell activation / Collagen / Cytokines / Edema / Erythema / Fitness equipment / Joint diseases / Kinases / Muscle strength / Muscles / MyoD protein / Myogenin / Patients / Protease inhibitors / Quality of life / Running / Sarcopenia / Satellite cells / Serum levels / Skeletal muscle / Statistical analysis / Statistics / Tumor necrosis factor-TNF / Weight